ArticleBMJ open diabetes research & care2021
Prevalence and incidence of microvascular and macrovascular complications over 15 years among patients with incident type 2 diabetes.
Article in BMJ open diabetes research & care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 5 syntheses or guidelines pooled it, 141 citations in OpenAlex.
- Prevalence of new-onset diabetes following COVID-19 infection: A systematic review and meta-analysis.Diabetes, obesity & metabolism · 2026Pooled it
- Association between glycated hemoglobin variability and risk of diabetic kidney disease and diabetic retinopathy in diabetic patients: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Association between serum uric acid levels and diabetic peripheral neuropathy in type 2 diabetes: a systematic review and meta-analysis.Frontiers in endocrinology · 2024Pooled it
- Weight-dependent and weight-independent effects of dulaglutide on blood pressure in patients with type 2 diabetes.Cardiovascular diabetology · 2023Pooled it
- Integrating Self-Management Education and Support in Routine Care of People With Type 2 Diabetes Mellitus: A Conceptional Model Based on Critical Interpretive Synthesis and A Consensus-Building Participatory Consultation.Frontiers in clinical diabetes and healthcare · 2022Pooled it
- Long-term safety and efficacy of imeglimin in Japanese individuals with type 2 diabetes and chronic kidney disease: A 52-week postmarketing clinical study (TWINKLE).Journal of diabetes investigation · 2025Trial
- Elevated fracture risk in a Danish cohort with type 2 diabetes mellitus and microvascular diseases.JBMR plus · 2026Article
- Suboptimal LDL-Cholesterol Control Under the 2019 ESC/EAS Dyslipidemia Guidelines: Results From the Nationwide TEMD-2 Study in Type 2 Diabetes.Diabetes, obesity & metabolism · 2026Article
- Artificial intelligence-enhanced electrocardiography for the prediction of future type 2 diabetes mellitus: a model-development and multicentre validation study.European heart journal. Digital health · 2026Article
- Basal Insulin Adherence in Patients with Type 2 Diabetes Mellitus in Routine Clinical Practice in Spain: Clinical and Economic Impact.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.PharmacoEconomics · 2026Article
- Selenium nanoparticle-loaded microneedle patches promote diabetic oral ulcer healing by regulating the inflammatory microenvironment through upregulation of SELENBP1-mediated mitophagy.Journal of nanobiotechnology · 2026Article
- Predictors of glycemic control with imeglimin for type 2 diabetes: Results of machine learning analyses using clinical trial data.Journal of diabetes investigation · 2026Article
- A novel extracellular flux assay workflow uncovers impaired sciatic nerve mitochondrial respiration in diabetic db/db mice.Cell communication and signaling : CCS · 2026Article
- Integration of clinical and proteomic risk factors enhances prognostic modelling of incident vascular complications in type 2 diabetes.Cardiovascular diabetology · 2026Article
- The Natural History of Prediabetes and Cardiovascular Disease in the Pediatric Population.Biomedicines · 2026Review
- Intestinal Permeability Biomarkers for Predicting Cardiometabolic Risk in Type 2 Diabetes Mellitus.Nutrients · 2026Article
- Shared and distinct metabolomics profiles associated with microvascular complications in the Diabetes Prevention Program Outcomes Study.Diabetologia · 2026Article
- The Application of Omics Technologies in Type II Diabetes Mellitus Research.Current diabetes reviews · 2026Review
- Cost-Consequences of Adding Gliclazide Modified Release to Metformin in Patients with Uncontrolled Type 2 Diabetes in the United Arab Emirates.Advances in therapy · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionType 2 diabetes (T2D) is a common condition that, if left untreated or poorly managed, can lead to adverse microvascular and macrovascular complications. We estimated the prevalence and incidence of microvascular and macrovascular complications among patients newly diagnosed with T2D within a US integrated healthcare system. RESEARCH DESIGN AND
methodsWe conducted a retrospective cohort study among patients newly diagnosed with T2D between 2003 and 2014. We evaluated 13 complications, including chronic kidney disease (CKD), cardiovascular disease (CVD), and all-cause mortality through 2018. Multivariable Cox proportional hazards models were used to study factors associated with complications.
resultsWe identified 135 199 patients with incident T2D. The mean age was 58 years, and 48% were women. The prevalence of CKD was the highest of the complications at the time of T2D diagnosis (prevalence=12.3%, 95% CI 12.2% to 12.5%), while the prevalence of CVD was among the lowest at 3.3% (95% CI 3.2% to 3.3%). The median time to incidence of a T2D complication ranged from 3.0 to 5.2 years. High incidence rates (95% CI) of T2D complications included peripheral neuropathy (26.9, 95% CI 26.5 to 27.3 per 1000 person-years (PY)), CKD (21.2, 95% CI 20.9 to 21.6 per 1000 PY), and CVD (11.9, 95% CI 11.7 to 12.2 per 1000 PY). The trend of 5-year incidence rates of T2D complications by diagnosis year decreased over time (p value<0.001). Older age, non-Hispanic white race/ethnicity, sex, higher A1C, smoking, and hypertension were associated with increased CKD and CVD incidence.
conclusionThough incidence rates of T2D complications were lower in more recent years (2010-2014), a significant proportion of patients had complications at T2D diagnosis. Earlier preventive therapies as well as managing modifiable factors may help delay the development and progression of T2D complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.